KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Other Operating Expenses (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Other Operating Expenses for 8 consecutive years, with $43.1 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 7.94% to $43.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $167.6 million through Dec 2025, up 2.37% year-over-year, with the annual reading at $167.6 million for FY2025, 2.37% up from the prior year.
  • Other Operating Expenses hit $43.1 million in Q4 2025 for Adaptive Biotechnologies, up from $42.1 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $67.4 million in Q4 2023 to a low of $31.0 million in Q1 2021.
  • Historically, Other Operating Expenses has averaged $41.2 million across 5 years, with a median of $40.4 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: soared 88.81% in 2021 and later plummeted 40.69% in 2024.
  • Year by year, Other Operating Expenses stood at $41.5 million in 2021, then decreased by 1.8% to $40.7 million in 2022, then soared by 65.41% to $67.4 million in 2023, then tumbled by 40.69% to $40.0 million in 2024, then increased by 7.94% to $43.1 million in 2025.
  • Business Quant data shows Other Operating Expenses for ADPT at $43.1 million in Q4 2025, $42.1 million in Q3 2025, and $42.0 million in Q2 2025.